Linked polymorphisms upstream of exons 1 and 2 of the human cholecystokinin gene are not associated with schizophrenia or bipolar disorder

T. Bowen, Nadine Norton, N. J O Jacobsen, C. Guy, J. K. Daniels, R. D. Sanders, A. G. Cardno, L. A. Jones, K. C. Murphy, P. McGuffin, N. Craddock, M. C. O'Donovan, M. J. Owen

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The evidence for a significant genetic contribution to the functional psychoses (schizophrenia and bipolar disorder) is now well established. However, in both cases, the non-mendelian mode of inheritance has made the identification of susceptibility loci particularly challenging. The neuropeptide cholecystokinin (CCK) is present both in the gut and the CNS. Studies of CCK-like immunoreactivity and CCK mRNA levels in human brains have revealed high concentrations in numerous loci and shown colocalisation of CCK with, for example, dopamine and tyrosine hydroxylase. Furthermore, antagonists of CCK-B receptors, which are found most frequently in the brain, inhibit the activity of brain dopamine neurons. Such findings suggest that, with respect to neuropsychiatric disorders, CCK is a suitable candidate for analysis using methods to detect gene variations which have the potential to affect protein structure or expression. In the present study, mutation analyses were carried out on the human CCK gene. Linked polymorphisms were found in the promoter region and in intron 1 close to the 3' mRNA splice acceptor site. However, the allele frequencies of these polymorphisms in samples of individuals affected with either schizophrenia (n = 117) or bipolar disorder (n = 124) did not differ from those of control subjects (n = 234), suggesting that these variations do not confer a predisposition to either of the functional psychoses.

Original languageEnglish (US)
Pages (from-to)67-71
Number of pages5
JournalMolecular Psychiatry
Volume3
Issue number1
StatePublished - 1998
Externally publishedYes

Fingerprint

Cholecystokinin
Bipolar Disorder
Exons
Schizophrenia
Genes
Psychotic Disorders
Brain
Cholecystokinin B Receptor
Messenger RNA
RNA Splice Sites
Dopaminergic Neurons
Tyrosine 3-Monooxygenase
Neuropeptides
Genetic Promoter Regions
Gene Frequency
Introns
Dopamine
Mutation
Proteins

Keywords

  • Bipolar disorder
  • Cholecystokinin
  • DNA mutational analysis
  • Polymorphism
  • Promoter regions
  • RNA splicing
  • Schizophrenia
  • Single-stranded conformational

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health

Cite this

Linked polymorphisms upstream of exons 1 and 2 of the human cholecystokinin gene are not associated with schizophrenia or bipolar disorder. / Bowen, T.; Norton, Nadine; Jacobsen, N. J O; Guy, C.; Daniels, J. K.; Sanders, R. D.; Cardno, A. G.; Jones, L. A.; Murphy, K. C.; McGuffin, P.; Craddock, N.; O'Donovan, M. C.; Owen, M. J.

In: Molecular Psychiatry, Vol. 3, No. 1, 1998, p. 67-71.

Research output: Contribution to journalArticle

Bowen, T, Norton, N, Jacobsen, NJO, Guy, C, Daniels, JK, Sanders, RD, Cardno, AG, Jones, LA, Murphy, KC, McGuffin, P, Craddock, N, O'Donovan, MC & Owen, MJ 1998, 'Linked polymorphisms upstream of exons 1 and 2 of the human cholecystokinin gene are not associated with schizophrenia or bipolar disorder', Molecular Psychiatry, vol. 3, no. 1, pp. 67-71.
Bowen, T. ; Norton, Nadine ; Jacobsen, N. J O ; Guy, C. ; Daniels, J. K. ; Sanders, R. D. ; Cardno, A. G. ; Jones, L. A. ; Murphy, K. C. ; McGuffin, P. ; Craddock, N. ; O'Donovan, M. C. ; Owen, M. J. / Linked polymorphisms upstream of exons 1 and 2 of the human cholecystokinin gene are not associated with schizophrenia or bipolar disorder. In: Molecular Psychiatry. 1998 ; Vol. 3, No. 1. pp. 67-71.
@article{75e5e44a6488439eb78768447512fcb7,
title = "Linked polymorphisms upstream of exons 1 and 2 of the human cholecystokinin gene are not associated with schizophrenia or bipolar disorder",
abstract = "The evidence for a significant genetic contribution to the functional psychoses (schizophrenia and bipolar disorder) is now well established. However, in both cases, the non-mendelian mode of inheritance has made the identification of susceptibility loci particularly challenging. The neuropeptide cholecystokinin (CCK) is present both in the gut and the CNS. Studies of CCK-like immunoreactivity and CCK mRNA levels in human brains have revealed high concentrations in numerous loci and shown colocalisation of CCK with, for example, dopamine and tyrosine hydroxylase. Furthermore, antagonists of CCK-B receptors, which are found most frequently in the brain, inhibit the activity of brain dopamine neurons. Such findings suggest that, with respect to neuropsychiatric disorders, CCK is a suitable candidate for analysis using methods to detect gene variations which have the potential to affect protein structure or expression. In the present study, mutation analyses were carried out on the human CCK gene. Linked polymorphisms were found in the promoter region and in intron 1 close to the 3' mRNA splice acceptor site. However, the allele frequencies of these polymorphisms in samples of individuals affected with either schizophrenia (n = 117) or bipolar disorder (n = 124) did not differ from those of control subjects (n = 234), suggesting that these variations do not confer a predisposition to either of the functional psychoses.",
keywords = "Bipolar disorder, Cholecystokinin, DNA mutational analysis, Polymorphism, Promoter regions, RNA splicing, Schizophrenia, Single-stranded conformational",
author = "T. Bowen and Nadine Norton and Jacobsen, {N. J O} and C. Guy and Daniels, {J. K.} and Sanders, {R. D.} and Cardno, {A. G.} and Jones, {L. A.} and Murphy, {K. C.} and P. McGuffin and N. Craddock and O'Donovan, {M. C.} and Owen, {M. J.}",
year = "1998",
language = "English (US)",
volume = "3",
pages = "67--71",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Linked polymorphisms upstream of exons 1 and 2 of the human cholecystokinin gene are not associated with schizophrenia or bipolar disorder

AU - Bowen, T.

AU - Norton, Nadine

AU - Jacobsen, N. J O

AU - Guy, C.

AU - Daniels, J. K.

AU - Sanders, R. D.

AU - Cardno, A. G.

AU - Jones, L. A.

AU - Murphy, K. C.

AU - McGuffin, P.

AU - Craddock, N.

AU - O'Donovan, M. C.

AU - Owen, M. J.

PY - 1998

Y1 - 1998

N2 - The evidence for a significant genetic contribution to the functional psychoses (schizophrenia and bipolar disorder) is now well established. However, in both cases, the non-mendelian mode of inheritance has made the identification of susceptibility loci particularly challenging. The neuropeptide cholecystokinin (CCK) is present both in the gut and the CNS. Studies of CCK-like immunoreactivity and CCK mRNA levels in human brains have revealed high concentrations in numerous loci and shown colocalisation of CCK with, for example, dopamine and tyrosine hydroxylase. Furthermore, antagonists of CCK-B receptors, which are found most frequently in the brain, inhibit the activity of brain dopamine neurons. Such findings suggest that, with respect to neuropsychiatric disorders, CCK is a suitable candidate for analysis using methods to detect gene variations which have the potential to affect protein structure or expression. In the present study, mutation analyses were carried out on the human CCK gene. Linked polymorphisms were found in the promoter region and in intron 1 close to the 3' mRNA splice acceptor site. However, the allele frequencies of these polymorphisms in samples of individuals affected with either schizophrenia (n = 117) or bipolar disorder (n = 124) did not differ from those of control subjects (n = 234), suggesting that these variations do not confer a predisposition to either of the functional psychoses.

AB - The evidence for a significant genetic contribution to the functional psychoses (schizophrenia and bipolar disorder) is now well established. However, in both cases, the non-mendelian mode of inheritance has made the identification of susceptibility loci particularly challenging. The neuropeptide cholecystokinin (CCK) is present both in the gut and the CNS. Studies of CCK-like immunoreactivity and CCK mRNA levels in human brains have revealed high concentrations in numerous loci and shown colocalisation of CCK with, for example, dopamine and tyrosine hydroxylase. Furthermore, antagonists of CCK-B receptors, which are found most frequently in the brain, inhibit the activity of brain dopamine neurons. Such findings suggest that, with respect to neuropsychiatric disorders, CCK is a suitable candidate for analysis using methods to detect gene variations which have the potential to affect protein structure or expression. In the present study, mutation analyses were carried out on the human CCK gene. Linked polymorphisms were found in the promoter region and in intron 1 close to the 3' mRNA splice acceptor site. However, the allele frequencies of these polymorphisms in samples of individuals affected with either schizophrenia (n = 117) or bipolar disorder (n = 124) did not differ from those of control subjects (n = 234), suggesting that these variations do not confer a predisposition to either of the functional psychoses.

KW - Bipolar disorder

KW - Cholecystokinin

KW - DNA mutational analysis

KW - Polymorphism

KW - Promoter regions

KW - RNA splicing

KW - Schizophrenia

KW - Single-stranded conformational

UR - http://www.scopus.com/inward/record.url?scp=14444283890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14444283890&partnerID=8YFLogxK

M3 - Article

C2 - 9491815

AN - SCOPUS:14444283890

VL - 3

SP - 67

EP - 71

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 1

ER -